|
TAVI Haemodynamics and Outcomes: Are We Measuring Appropriately? |
- 1.00 European Board for Accreditation in Cardiology (EBAC)
|
|
Optimising Treatment of HF |
- 1.00 European Board for Accreditation in Cardiology (EBAC)
|
|
P2Y12 Receptor Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: An Assessment of Current Evidence |
- 1.00 European Board for Accreditation in Cardiology (EBAC)
|
|
Hypertrophic Cardiomyopathy in Review: Highlights 2019-2021 |
- 0.25 AMA PRA Category 1 Credit™
|
|
Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice |
- 1.00 Malaysian Medical Association (MMA)
|
|
Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme |
- 1.00 Malaysian Medical Association (MMA)
|
|
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice |
- 1.00 European Board for Accreditation in Cardiology (EBAC)
|
|
Dual antiplatelet therapy for acute stroke and TIA: Current best practice and emerging strategies |
- 1.00 European Board for Accreditation in Cardiology (EBAC)
|
Facebook
Twitter
LinkedIn
Forward
